Allergy Treatment Ladder: When Immunotherapy Becomes the Right Next Step

Allergen immunotherapy is appropriate to consider when allergy symptoms are not adequately controlled by first-line medications (antihistamines and nasal corticosteroids), when medications produce unacceptable side effects, or when you prefer a treatment that modifies the underlying disease rather than managing symptoms indefinitely. Per AAAAI/ACAAI guidelines (Cox et al., JACI 2011), prior medication failure is not an absolute prerequisite — AIT may be offered as an initial disease-modifying option for motivated patients who have confirmed allergen-specific IgE sensitization and symptoms that significantly affect quality of life. Children with allergic rhinitis have an additional specific indication: SCIT can reduce asthma development by approximately 40% at 10-year follow-up (Jacobsen, Allergy 2007), making early consideration appropriate for pediatric patients.

Symptom treatments — antihistamines, nasal corticosteroids, decongestants, and leukotriene antagonists — block or reduce the allergic response downstream, after the immune system has already misidentified the allergen as dangerous. They control symptoms effectively while you take them, but provide no benefit after stopping. Allergen immunotherapy reprograms the immune system upstream, inducing regulatory T cells and IgG4 blocking antibodies that prevent the allergic cascade from being triggered. This is why immunotherapy produces benefits lasting 3 to 12 years after stopping a completed course (Durham, NEJM 1999; Eng, Allergy 2006), while antihistamine effects disappear within hours and nasal corticosteroid benefits within days of stopping. The WHO classifies immunotherapy as the only disease-modifying allergy treatment — no pharmacotherapy alternative achieves this status.

Allergy shots (SCIT) and sublingual drops are both valid immunotherapy choices, with the best option depending on your allergen profile, lifestyle, and preference. Network meta-analyses find comparable efficacy for the allergens covered by FDA-approved SLIT tablets (Nelson 2015). SCIT was traditionally tied to weekly clinic visits with a 30-minute post-injection observation, but telehealth programs such as Curex now let eligible maintenance patients self-administer the shot at home — with a prescribed epinephrine auto-injector on hand and the first dose and every dose change supervised live over Zoom. SCIT is preferred for polysensitized patients needing custom multi-allergen formulations not available in any single FDA-approved tablet. Sublingual drops suit patients with needle sensitivity or limited allergist access. On systemic safety, SLIT has zero confirmed worldwide fatalities versus roughly 1 per 2.5 million injections for SCIT historically (Bernstein et al., JACI 2004), a risk managed by the supervision and epinephrine access built into SCIT.

Evidence supports a meaningful asthma-prevention effect from allergen immunotherapy in children with allergic rhinoconjunctivitis. The PAT study (Jacobsen, Allergy 2007, 10-year follow-up of 205 children) found asthma in only 25% of SCIT-treated children versus 45% of controls seven years after stopping treatment — an odds ratio of 2.5 favoring SCIT. A large German insurance database study (Schmitt et al., JACI 2015, over 118,000 patients) confirmed reduced asthma incidence and medication use with AIT versus matched controls. The biological mechanism is consistent with these findings: early AIT interrupts the Th2-dominant immune program before it broadens from nasal to bronchial disease. Most guidelines now recognize asthma prevention as an established benefit of appropriately selected immunotherapy in pollen-allergic children, though it is not guaranteed for every patient.

Several clinical indicators suggest immunotherapy is appropriate rather than continuing long-term medications. Symptom burden: moderate-to-severe rhinitis symptoms affecting sleep, work, or quality of life despite maximal pharmacotherapy. Treatment duration preference: if the prospect of taking daily antihistamines indefinitely is unappealing, immunotherapy's 3-5 year course with lasting benefit may be preferable. Disease trajectory: in children, allergic rhinitis that begins to affect lower airways (early asthma symptoms) or in patients who are monosensitized and wish to prevent new sensitizations. Safety of current medications: montelukast's FDA black box warning for neuropsychiatric effects (2020) has made many patients and families reconsider long-term use. The prerequisite for immunotherapy consideration is confirmed IgE-mediated sensitization — positive allergy testing — which your allergist can verify by skin prick test or serum-specific IgE.

Over a 10-year horizon, allergen immunotherapy often costs less than long-term symptom medications while delivering the added benefit of disease modification. Hankin et al. (Ann Allergy 2010, matched cohort) found AIT-treated patients had 33% lower total 18-month healthcare costs than untreated controls, with savings emerging within 3 months. In-clinic allergy shots cost $800-4,000 per year in copays, facility, and preparation charges (varies by insurance and allergen count); at-home allergy shots through Curex are a flat $129/month, and completing treatment ends ongoing costs. By contrast, prescription nasal corticosteroids cost $600-1,800 annually indefinitely, and OTC antihistamines add $200-400 per year — with no endpoint and no disease modification. Adding indirect costs (lost workdays, productivity loss) strengthens immunotherapy's value further: Pokladnikova et al. (Ann Allergy 2008) found allergy patients missed 14 workdays and had 16 hours of reduced productivity annually before treatment.